These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1694507)

  • 1. A 90-day subcutaneous toxicity and fertility study of a LHRH antagonist in rats.
    Sundaram K; Didolkar AK; Keizer-Zucker A; DeJesus W; Rivier J; Vale W; Bardin CW
    Fundam Appl Toxicol; 1990 May; 14(4):734-44. PubMed ID: 1694507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of concordant luteinizing hormone (LH), testosterone, and alpha-subunit pulses after LH-releasing hormone antagonist administration in normal men.
    Pavlou SN; Veldhuis JD; Lindner J; Souza KH; Urban RJ; Rivier JE; Vale WW; Stallard DJ
    J Clin Endocrinol Metab; 1990 May; 70(5):1472-8. PubMed ID: 2110578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men.
    Pavlou SN; Wakefield G; Schlechter NL; Lindner J; Souza KH; Kamilaris TC; Konidaris S; Rivier JE; Vale WW; Toglia M
    J Clin Endocrinol Metab; 1989 Feb; 68(2):446-54. PubMed ID: 2537334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of administration of a gonadotropin-releasing hormone (GnRH) antagonist (Nal-Glu) during the periovulatory period: the luteinizing hormone surge requires secretion of GnRH.
    Dubourdieu S; Charbonnel B; D'Acremont MF; Carreau S; Spitz IM; Bouchard P
    J Clin Endocrinol Metab; 1994 Feb; 78(2):343-7. PubMed ID: 8106622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose effects of the gonadotropin-releasing hormone antagonist, Nal-Glu, combined with testosterone enanthate on gonadotropin levels in normal men.
    Bagatell CJ; Rivier JE; Bremner WJ
    Fertil Steril; 1995 Jul; 64(1):139-45. PubMed ID: 7789550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gonadotropin-releasing hormone antagonists with N omega-triazolylornithine, -lysine, or -p-aminophenylalanine residues at positions 5 and 6.
    Rivier J; Porter J; Hoeger C; Theobald P; Craig AG; Dykert J; Corrigan A; Perrin M; Hook WA; Siraganian RP
    J Med Chem; 1992 Nov; 35(23):4270-8. PubMed ID: 1280300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent pituitary-gonadal axis suppression and extremely low anaphylactoid activity of a new gonadotropin releasing hormone (GnRH) receptor antagonist "azaline B".
    Campen CA; Lai MT; Kraft P; Kirchner T; Phillips A; Hahn DW; Rivier J
    Biochem Pharmacol; 1995 May; 49(9):1313-21. PubMed ID: 7763313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential regulation of luteinizing hormone, follicle-stimulating hormone, and free alpha-subunit secretion from the gonadotrope by gonadotropin-releasing hormone (GnRH): evidence from the use of two GnRH antagonists.
    Hall JE; Whitcomb RW; Rivier JE; Vale WW; Crowley WF
    J Clin Endocrinol Metab; 1990 Feb; 70(2):328-35. PubMed ID: 2105329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the suppressive effects of testosterone and a potent new gonadotropin-releasing hormone antagonist on gonadotropin and inhibin levels in normal men.
    Bagatell CJ; McLachlan RI; de Kretser DM; Burger HG; Vale WW; Rivier JE; Bremner WJ
    J Clin Endocrinol Metab; 1989 Jul; 69(1):43-8. PubMed ID: 2499592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
    Bagatell CJ; Matsumoto AM; Christensen RB; Rivier JE; Bremner WJ
    J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-dose administration of the gonadotropin-releasing hormone antagonist, Nal-Lys (antide) to healthy men.
    Bagatell CJ; Conn PM; Bremner WJ
    Fertil Steril; 1993 Oct; 60(4):680-5. PubMed ID: 8405525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of corpus luteum function by the gonadotropin-releasing hormone antagonist Nal-Glu: effect of the dose and timing of human chorionic gonadotropin administration.
    Dubourdieu S; Charbonnel B; Massai MR; Marraoui J; Spitz I; Bouchard P
    Fertil Steril; 1991 Sep; 56(3):440-5. PubMed ID: 1894021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Species differences in the sensitivity to the antitesticular effects of [Ac-D-NAL(2)1, 4FD-Phe2, D-Trp3,D-Arg6]-LHRH, a potent LHRH antagonist.
    Sundaram K; Schmidt F; Thau RB; Rivier J; Vale W; Bardin CW
    Contraception; 1984 Mar; 29(3):271-81. PubMed ID: 6375958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75).
    Bokser L; Srkalovic G; Szepeshazi K; Schally AV
    Neuroendocrinology; 1991 Aug; 54(2):136-45. PubMed ID: 1662786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the antigonadotropic activity of three GnRH antagonists (Nal-Glu, Antide and Cetrorelix) in a non-human primate model (Macaca fascicularis).
    Weinbauer GF; Nieschlag E
    Andrologia; 1993; 25(3):141-7. PubMed ID: 8517553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marked suppression of gonadotropins and testosterone by an antagonist analog of gonadotropin-releasing hormone in men.
    Salameh W; Bhasin S; Steiner B; McAdams LA; Peterson M; Swerdloff R
    Fertil Steril; 1991 Jan; 55(1):156-64. PubMed ID: 1898888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of two different delivery systems on gonadotropin-releasing hormone (GnRH) antagonist-induced suppression of gonadotropins and testosterone in man.
    Salameh W; Bhasin S; Steiner BS; McAdams LA; Peterson M; Rivier JE; Vale WW; Swerdloff RS
    J Androl; 1994; 15(1):22-8. PubMed ID: 8188535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppressive actions of a gonadotropin-releasing hormone antagonist on luteinizing hormone, follicle-stimulating hormone, and prolactin release in estrogen-deficient postmenopausal women.
    Urban RJ; Pavlou SN; Rivier JE; Vale WW; Dufau ML; Veldhuis JD
    Am J Obstet Gynecol; 1990 May; 162(5):1255-60. PubMed ID: 2111095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of pituitary glycoprotein alpha-subunit secretion after administration of a luteinizing hormone-releasing hormone antagonist in normal men.
    Lindner J; Rivier JE; Vale WW; Pavlou SN
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1219-24. PubMed ID: 1690747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.